Study title:
Neurology. 2004 Dec 14;63(11):2097-103.
Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin
disease.
Varrone A, Pellecchia MT, Amboni M, Sansone V, Salvatore E, Ghezzi D, Garavaglia
B, Brice A, Brunetti A, Bonavita V, De Michele G, Salvatore M, Pappatà S, Barone
P.
Neurology. 2004 Dec 14;63(11):2097-103.
Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin
disease.
Varrone A, Pellecchia MT, Amboni M, Sansone V, Salvatore E, Ghezzi D, Garavaglia
B, Brice A, Brunetti A, Bonavita V, De Michele G, Salvatore M, Pappatà S, Barone
P.
Type of medicine: Centrally authorised medicines
|
Therapeutic area: Nervous System Diseases
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: ioflupane (123l) |
ATC code: V09A B 03 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: CLINICAL |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|